Clinical Trials Logo

Kasabach-Merritt Syndrome clinical trials

View clinical trials related to Kasabach-Merritt Syndrome.

Filter by:

NCT ID: NCT05351216 Recruiting - Clinical trials for Kaposiform Hemangioendothelioma

The Effect of Sirolimus on Immunizations During the Treatment of Kaposiform Hemangioendothelioma

Start date: March 1, 2021
Phase:
Study type: Observational

To research and explore the antibody protection and immune memory after vaccination in children with KHE during sirolimus administration. To explore the feasibility (safety and efficacy) of vaccination in a timely manner during the administration of sirolimus in children with KHE. To search for back-up plans for vaccination regimens for KHE patients taking sirolimus in children who do not respond to primary vaccination.

NCT ID: NCT05324384 Recruiting - Clinical trials for Hemangioendothelioma

Different Doses of Sirolimus for the Maintenance Treatment of Kaposiform Hemangioendothelioma

Start date: April 5, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of different doses of sirolimus in the maintenance treatment of kaposiform hemangioendothelioma.

NCT ID: NCT04775173 Completed - Clinical trials for Kaposiform Hemangioendothelioma

Efficacy and Safety of Different Concentrations of Sirolimus in the Treatment of Kaposiform Hemangioendothelioma.

Start date: February 17, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of different concentration gradients of sirolimus in the treatment of Kaposiform hemangioendothelioma.

NCT ID: NCT04448873 Completed - Clinical trials for Kaposiform Hemangioendothelioma

Guided Discontinuation Versus Maintenance Treatment of Sirolimus in Pediatric Patients With Kaposiform Hemangioendothelioma

Start date: July 1, 2020
Phase: Phase 4
Study type: Interventional

This randomized controlled trial aims to compare guided discontinuation with maintenance treatment of sirolimus in pediatric patients with KHE.

NCT ID: NCT04409691 Not yet recruiting - Clinical trials for Kaposiform Hemangioendothelioma (KHE) With Kasabach-Merritt Phenomenon (KMP)

SCMC Trial on KHE With KMP (V.2020)

SCMC-KK2020
Start date: July 1, 2020
Phase: Phase 1
Study type: Interventional

a phase I trial focusing on safety and efficacy of prednison shock plus sirolimus maintenance in treating Kaposiform hemangioendothelioma (KHE) with Kasabach-Merritt phenomenon (KMP)

NCT ID: NCT04077515 Completed - Hemangioma Clinical Trials

Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma

Start date: May 1, 2019
Phase: Phase 4
Study type: Interventional

to evaluate the safety and efficacy of Low-dose sirolimus in Kaposiform Hemangioendothelioma in Chinese children by a prospective, randomized open trial.

NCT ID: NCT04056962 Recruiting - Clinical trials for Tacrolimus, Kaposiform Hemangioendothelioma, Tufted Angioma

Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma

Start date: September 1, 2019
Phase: Phase 2
Study type: Interventional

The aim of this study was to evaluate the efficacy and safety of topical application of tacrolimus at different concentrations for superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA).

NCT ID: NCT03188068 Completed - Clinical trials for Kaposiform Hemangioendothelioma

Sirolimus Versus Sirolimus Plus Prednisolone for Kaposiform Hemangioendothelioma

Start date: June 1, 2017
Phase: Phase 2
Study type: Interventional

Kaposiform hemangioendothelioma (KHE) is a rare vascular neoplasm that occurs predominantly in infancy or early childhood. KHE has a nearly equal sex ratio. The annual incidence of KHE has been estimated at 0.071 per 100,000 children. KHE presents with intermediate-malignant and locally aggressive characteristics but without distant metastases. This pilot trial studies sirolimus versus sirolimus plus pednisolone in treating patients diagnosed with kaposiform hemangioendothelioma (KHE) and Kasabach-Merritt phenomemon (KMP) that cannot be removed by surgery. The purpose of this study is to compare the efficacy and safety of orally administered sirolimus versus sirolimus plus pednisolone in the treatment of KHE associated with KMP.

NCT ID: NCT02110069 Terminated - Tufted Angioma Clinical Trials

A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors

Start date: June 14, 2017
Phase: Phase 2
Study type: Interventional

In this research study we want to learn more about which treatment works better for patients diagnosed with a vascular tumor called Kaposiform Hemangioendothelioma (KHE) or other high risk vascular tumors such as Tufted Angioma (TA). In these tumors, the blood cells that help your blood clot called platelets become trapped in the tumor causing swelling, pain, and bruising. Vascular tumors can be life threatening. There are few medical treatments that will work to shrink the vascular tumor. Some doctors will use steroids and vincristine to try and shrink vascular tumors. In this research study, the study doctor will compare two different drugs to see which one will work better to help shrink your vascular tumor. One of the drugs is vincristine. Vincristine is approved by the Food and Drug Administration (FDA) to treat people with cancer. Vincristine is used to stop the abnormal cells from growing such as cells that make up blood vessels. The other drug to be used in this study is sirolimus. Sirolimus is currently approved by the Food and Drug Administration (FDA) to prevent transplanted organ rejection. Sirolimus is not approved by the FDA for treatment of vascular abnormalities and is considered experimental. Sirolimus belongs to a class of drugs call 'mTOR inhibitors'. mTOR (mammilian target of rapamycin) helps cells to grow and may also help blood vessels to grow in a more normal fashion. Sirolimus is currently being tested in patients with vascular tumors and cancer. In vascular tumors, we hope sirolimus will stop the blood vessel growth. Funding Source: FDA - OOPD (Office of Orphan Products Development)

NCT ID: NCT00975819 Active, not recruiting - Clinical trials for Microcystic Lymphatic Malformation

Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies

Start date: October 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if the use of sirolimus in the treatment of children and young adults with complicated vascular anomalies will prove to be safe and provide objective response resulting in improved clinical status and quality of life. Funding Source - FDA OOPD (Food and Drug Administration - Office of Orphan Products Development)